EP Patent

EP4532713A1 — Identification of nanoparticles for preferential tissue or cell targeting

Assigned to Beam Therapeutics Inc · Expires 2025-04-09 · 1y expired

What this patent protects

[0251] Provided herein includes high-throughput methods for in vivo screening nanoparticles (e.g., lipid nanoparticles) for preferential delivery to a target tissue or cell type. Also provided are compositions used in the high-throughput nanoparticle screening method.

USPTO Abstract

[0251] Provided herein includes high-throughput methods for in vivo screening nanoparticles (e.g., lipid nanoparticles) for preferential delivery to a target tissue or cell type. Also provided are compositions used in the high-throughput nanoparticle screening method.

Drugs covered by this patent

Patent Metadata

Patent number
EP4532713A1
Jurisdiction
EP
Classification
—
Expires
2025-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Beam Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.